Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells

Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in the chronic phase (CML-CP). However, it is unlikely that they can completely “cure” the disease. This might be because some subpopulations of CML-CP cells such as stem and progenitor cells are resistant to...

Descripción completa

Detalles Bibliográficos
Autores principales: Flis, Sylwia, Bratek, Ewelina, Chojnacki, Tomasz, Piskorek, Marlena, Skorski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826736/
https://www.ncbi.nlm.nih.gov/pubmed/31614827
http://dx.doi.org/10.3390/cancers11101544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826736/
https://www.ncbi.nlm.nih.gov/pubmed/31614827
http://dx.doi.org/10.3390/cancers11101544

Ejemplares similares